Related Experiment Video
Updated: Mar 29, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?
Iulia Cristina Marginean1, Sergiu Marian Cazacu2, Cristina Maria Marginean3
1Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Insights
Managing anticoagulation in liver cirrhosis patients with atrial fibrillation requires balancing bleeding and clotting risks. Direct oral anticoagulants (DOACs) show promise but need further study for optimal use in chronic liver disease.
Area of Science:
- Cardiology
- Hepatology
- Pharmacology
Background:
- Anticoagulant use in chronic liver diseases (CLD), including metabolic steatohepatitis (MASH), metabolic associated steatotic liver disease (MASLD), and liver cirrhosis (LC), presents significant clinical challenges.
- Alcohol-related LC is frequently associated with atrial fibrillation (AF), necessitating anticoagulation while managing heightened thrombosis and bleeding risks.
Purpose of the Study:
- To explore the use of direct oral anticoagulants (DOACs) in patients with alcohol-related liver cirrhosis and atrial fibrillation.
- To examine the balance between thrombotic complications and bleeding risks associated with DOACs in this patient population.
Main Methods:
- Review of current literature on anticoagulation in patients with CLD and AF.
- Analysis of the safety and efficacy profiles of DOACs compared to warfarin.
- Evaluation of DOACs' suitability across different stages of liver cirrhosis (Child-Pugh A, B, C).
Main Results:
- DOACs are effective and safe alternatives to warfarin for stroke prevention in AF patients with Child-Pugh A and B cirrhosis (excluding rivaroxaban).
- DOACs are contraindicated in Child-Pugh C cirrhosis.
- DOACs offer advantages in administration, drug interactions, safety, and efficacy.
Conclusions:
- Individualized, multidisciplinary management is crucial for patients with AF and LC.
- Further randomized controlled trials with defined cirrhosis stages and anticoagulation protocols are needed to guide clinical practice.
- DOACs represent a valuable therapeutic option when carefully selected and monitored in specific CLD patient subgroups.
Abstract:
A significant clinical challenge is represented by the use of anticoagulants in patients with chronic liver diseases-such as metabolic steatohepatitis (MASH), metabolic associated steatotic liver disease (MASLD), and liver cirrhosis (LC). There is a well-established association between alcohol-related LC and atrial fibrillation (AF). These individuals often require anticoagulation, but treatment must carefully balance the heightened risks of both thrombosis and bleeding. Direct oral anticoagulants (DOACs) are recognized as effective and safe alternatives to warfarin, offering superior stroke prevention and a more favorable safety profile regarding major bleeding. They are generally considered safe for use in patients with LC classified as Child-Pugh A and B-excluding rivaroxaban-but are contraindicated in those with Child-Pugh C cirrhosis. DOACs also offer practical advantages, including convenience of administration, fewer drug interactions, and a high level of safety and efficacy. Comprehensive randomized controlled trials with well-defined cirrhosis stages and standardized anticoagulation protocols are essential to guide clinical decision-making. Until then, a multidisciplinary, individualized approach remains critical in managing patients with both AF and LC. The present review aims to explore the complex interplay between alcohol-related LC and the therapeutic use of direct oral anticoagulants (DOACs), particularly in the presence of cardiovascular risk factors such as atrial fibrillation, and the associated thrombotic complications.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...